Prokaryotic expression, purification and immunogenicity in rabbits of the small antigen of hepatitis delta virus by Tunitskaya, Vera L. et al.
 International Journal of 
Molecular Sciences
Communication
Prokaryotic Expression, Purification and
Immunogenicity in Rabbits of the Small Antigen of
Hepatitis Delta Virus
Vera L. Tunitskaya 1, Olesja V. Eliseeva 2, Vladimir T. Valuev-Elliston 1, Daria A. Tyurina 1,
Natalia F. Zakirova 1, Olga A. Khomich 1, Martins Kalis 3, Oleg E. Latyshev 2,
Elizaveta S. Starodubova 1, Olga N. Ivanova 1, Sergey N. Kochetkov 1, Maria G. Isaguliants 2,3,*
and Alexander V. Ivanov 1,*
1 Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Vavilov str. 32, Moscow 119991,
Russia; ve_tun@mail.ru (V.L.T.); gansfaust@mail.ru (V.T.V.-E.); tyurina.dascha@gmail.com (D.A.T.);
nat_zakirova@mail.ru (N.F.Z.); o.a.khomich@gmail.com (O.A.K.); estarodubova@yandex.ru (E.S.S.);
olgaum@yandex.ru; (O.N.I.); kochet@eimb.ru (S.N.K.)
2 Gamaleya Research Center of Epidemiology and Microbiology, Gamaleja str. 16, Moscow 123098, Russia;
oleglat80@mail.ru (O.V.E.); olesenka80@mail.ru (O.E.L.)
3 A Kirchenstein Institute of Microbiology and Virology, Research Department, Riga Stradins University,
Dzirciema iela 16, Riga LV-1007, Latvia; martins.kalis@rsu.lv
* Correspondence: maria.issagouliantis@rsu.lv or isaguliants@gamaleya.org (M.G.I.);
aivanov@yandex.ru (A.V.I.); Tel.: +371-25-244-801 (M.G.I.); +7-499-135-6065 (A.V.I.)
Academic Editor: Tatsuo Kanda
Received: 25 August 2016; Accepted: 27 September 2016; Published: 20 October 2016
Abstract: Hepatitis delta virus (HDV) is a viroid-like blood-borne human pathogen that accompanies
hepatitis B virus infection in 5% patients. HDV has been studied for four decades; however,
the knowledge on its life-cycle and pathogenesis is still sparse. The studies are hampered by
the absence of the commercially-available HDV-specific antibodies. Here, we describe a set of
reproducible methods for the expression in E. coli of His-tagged small antigen of HDV (S-HDAg),
its purification, and production of polyclonal anti-S-HDAg antibodies in rabbits. S-HDAg was
cloned into a commercial vector guiding expression of the recombinant proteins with the C-terminal
His-tag. We optimized S-HDAg protein purification procedure circumventing a low affinity of the
His-tagged S-HDAg to the Ni-nitrilotriacetyl agarose (Ni-NTA-agarose) resin. Optimization allowed
us to obtain S-HDAg with >90% purity. S-HDAg was used to immunize Shinchilla grey rabbits which
received 80 µg of S-HDAg in two subcutaneous primes in the complete, followed by four 40 µg
boosts in incomplete Freunds adjuvant. Rabbits were bled two weeks post each boost. Antibody
titers determined by indirect ELISA exceeded 107. Anti-S-HDAg antibodies detected the antigen on
Western blots in the amounts of up-to 100 pg. They were also successfully used to characterize the
expression of S-HDAg in the eukaryotic cells by immunofluorescent staining/confocal microscopy.
Keywords: hepatitis delta virus; prokaryotic expression; protein purification; rabbit immunization
1. Introduction
Hepatitis delta virus (HDV) is a defective viroid-like agent which infects patients on the
background of a newly acquired or an established infection with hepatitis B virus (HBV)
(co-, and super-infection, respectively), in both cases aggravating liver disease. Co-infection with
HDV and HBV in 95%–98% cases resolves as acute hepatitis B, but can also cause a severe fulminant
hepatitis. The latter results in a massive necrosis of hepatocytes, liver failure, and death in up to
80% of patients, if they cannot undergo liver transplantation. Superinfection, in contrast, results
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in the chronic disease in the majority (80%–90%) of cases. Chronic HBV/HDV infection presents
a more severe liver disease than chronic HBV mono-infection and is manifested by an accelerated
fibrosis progression, early decompensation in the settings of established cirrhosis, and an increased
risk of hepatocellular carcinoma attributed to the rapid development of cirrhosis (for a review see [1]).
Treatment of chronic HDV infection is difficult as it does not have an enzymatic function to target [2].
The only established therapy is treatment with the pegylated-interferon α, effective in 25%–30% of
cases [3,4]. Due to the introduction of massive HBV immunization of the newborn babies, and gradual
extension of the HBV vaccination to older subjects, risks of acquisition of HDV infection have notably
decreased [5]. However, infection with HDV is still a major health problem affecting 15 to 20 million
people worldwide, specifically in the countries where HBV vaccination is not performed, and in the
regions where HDV infection is endemic, as in the Middle East, Mediterranean area, Amazonian
region, some African countries, and parts of the Russian Federation [6,7].
HDV genome is presented by circular antigenomic RNA. It is replicated by the host RNA
polymerases generating genomic and mRNA forms. HDV RNA contains a single open reading
frame (ORF) encoding a protein of 195 amino acid residues referred to as the small HDV antigen
(24 kDa; S-HDAg). Antigenomic HDV RNA is partially edited by dsRNA-adenosine deaminase 1
(ADAR) [8] that converts the UAG stop codon to an amber UIG codon. The latter results in the
elongation of ORF which generates an extended 214 amino acid long protein referred to as the large
HDV antigen (27 kDa; L-HDAg). None of them exhibits any enzymatic activity. In the virus life
cycle, S-HDAg and L-HDAg act as the regulatory proteins. S-HDAg is important for virus replication,
whereas L-HDAg inhibits replication and leads to the assembly of the virion [9,10]. During virion
assembly, S-HDAg and L-HDAg form a capsid for antigenomic RNA. At the later stages of the virion
production, the capsids get surrounded by HBV surface antigens [10,11].
Patients with acute self-limiting HBV-HDV coinfection exhibit a panel of HDV specific serological
responses. Serum HDV RNA and HDV antigens may be detected early, concurrently with the detection
of HBV surface antigen (HBsAg). Disappearance of HDV antigen is followed by the seroconversion to
anti-hepatitis D antibodies, first IgM, and then IgG. HDV superinfection of HBV carriers is manifested
by the appearance of HDAg and HDV RNA, with a simultaneous reduction of HBV replication.
Patients with chronic HDV infection maintain high titers of anti-HDV IgM and IgG [12]. Diagnosis of
HDV infection based on serological testing and confirmation of replication by nucleic acid testing [13].
Several in-house assays and commercial PCR have been developed but their capacity to detect all
HDV genotypes remains questionable [14]. However, these assays are not yet standardized and the
results from different laboratories are often not comparable [15,16]. Major differences in the sensitivity
were also found for the immune assays detecting HDAg [16,17]. Moreover, there are no commercially
available antibodies for the detection of HDV antigen even for the research purposes. Anti-HDAg
antibodies were raised in rabbits [18,19], however, their availability for the scientific community was
always limited. Our goal was to fill this gap and generate antibodies against HDV antigens that could
be used in a variety of HDV-specific immune assays. This requested expression of the small HDV
antigen in quantities sufficient for raising polyclonal antibodies in laboratory animals, such as rabbits.
Hereby, we describe the detailed protocols for the expression and purification of the small antigen of
HDV in Escherichia coli, generation of polyclonal anti-HDV rabbit antibodies. The level of antibodies
directed against S-HDAg in rabbit serum was assessed by ELISA, and antibody affinity tested by
Western blot and immunofluorescence/confocal microscopy.
2. Results
2.1. Expression and Purification of Small HDV Antigen
Raising of specific antibodies requires sufficient amounts of pure antigen, in this case S-HDAg.
A plasmid for the expression of S-HDAg, pET-21d-SHDAg, was constructed based on the widely used
pET-21d vector for bacterial expression of the C-terminally His-tagged recombinant proteins. S-HDAg
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was expressed in the Rosetta (DE3) E. coli strain which carries a plasmid encoding “rare” tRNAs
required for the expression of the mammalian and viral genes. Plasmid pET-21d-SHDAg transformed
into the Rosetta (DE3) strain directed efficient production of S-HDAg (Figure 1).
The protein was purified using Ni-nitrilotriacetyl agarose (Ni-NTA-agarose) column. Earlier,
Ding et al. described low affinity of S-HDAg to the Ni-NTA-agarose [20]. Indeed, during the isolation
procedure we observed that despite very high protein levels in the cell lysate, only a minor fraction of
S-HDAg (<10%) was bound to the column (Figure 1). This may be due to the globular conformation
adopted by the major portion of the protein, preventing the hexahistidine tag from binding to the resin.
This problem was partially resolved by using large volumes of cell culture (1–2 L) and recycled loading
of the cell lysate onto the resin (lysates were allowed to pass the column two to three times instead of
one). This approach typically provided 1 mg of S-HDAg per 1 L of E. coli culture. Antigen purification
also required large (>10 resin volumes) volumes of the wash buffers. Once obtained, the protein was
dissolved in a Tris-HCl buffer containing 10% glycerol, 300 mM NaCl, and 1 mM 2-mercaptoethanol
and stored at +4 ◦C. In these conditions protein was intact for at least 50 h, longer incubations led to
gradual protein degradation. For a longer-term storage, S-HDAg was dialyzed against the same buffer
supplemented with 50% glycerol, aliquoted and kept frozen at −20 ◦C.
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Figure 1. Expression and purification of the His-tagged small antigen of hepatitis delta virus  
(S-HDAg). SDS-PAGE analysis of the lysates of uninduced and induced E. coli Rosetta (DE3) cells, 
and of the fractions obtained during purification of the recombinant antigen on the Ni-nitrilotriacetyl 
agarose (Ni-NTA-agarose) column. Concentration of imidazole used for elution of His-tagged  
S-HDAg from the Ni-NTA-agarose column is depicted over the wells. Molecular mass markers, in 
kDa, are given to the left. 
2.2. Rabbit Immunization and Evaluation of Rabbit Anti-S-HDAg 
Due to instability of S-HDAg, all immunizations were performed within the first 24 h after 
protein purification. Ten-week-old female rabbits were primed with subcutaneous and repeatedly 
boosted with intravenous injections of the freshly purified S-HDAg. Each animal received the total 
of 240 μg of the protein. Sera collected two weeks after each boost were assessed for the presence of 
anti-S HDAg antibodies by ELISA on plates coated with a freshly prepared S-HDAg lot. The initial 
antibody titer after the first boost equaled to 2 × 106, and the highest antibody titer after the third 
boost reached 2 × 107 (Figure 2). Further boosting led to a decrease of antibody titer as detected by 
ELISA (Figure 2). 
Figure 1. Expression and purification of the His-tagged small antigen of hepatitis delta virus (S-HDAg).
SDS-PAGE analysis of the l sates of uninduced a d induced E. coli Rosetta (DE3) cells, and of the
fracti ns obt ined during purification of the recombinant antigen on the Ni-nitrilotriacetyl ag rose
(Ni-NTA-agarose) column. Concentration of imidazole used for elution of His-tagged S-HDAg from
the Ni-NTA-agarose column is depicted over the wells. Mol cular mas mark rs, in kDa, are given to
the left.
2.2. Rabbit Immunization and Evaluation of Rabbit Anti-S-HDAg
Due to instability of S-HDAg, all immunizations were performed within the first 24 h after protein
purification. Ten-week-old female rabbits were primed with subcutaneous and repeatedly boosted
with intravenous injections of the freshly purified S-HDAg. Each animal received the total of 240 µg of
the protein. Sera collected two weeks after each boost were assessed for the presence of anti-S HDAg
antibodies by ELISA on plates coated with a freshly prepared S-HDAg lot. The initial antibody titer
after the first boost equaled to 2 × 106, and the highest antibody titer after the third boost reached
2 × 107 (Figure 2). Further boosting led to a decrease of antibody titer as detected by ELISA (Figure 2).
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2.4. Application of Anti-S-HDAg Antibodies for Immunofluorescence
Finally, we sought to evaluate to applicability of the sera for the detection of HDV antigens
by fluorescent/confocal microscopy. Huh7.5 cells were seeded on glass coverslips and transfected
with pDL444 encoding S-HDAg, or pDL445 encoding L-HDAg and let them grow for 24 to 48 h.
Two protocols were used to fix the cells. Methanol-acetone protocol was applied to fix cells 24 h
posttransfection, whereas cells at 48 h posttransfection were fixed by formaldehyde. In both cases,
anti-S-HDAg antibodies efficiently stained both small and large HDV antigens (Figure 4). In lines with
the earlier observations [21], both antigens exhibited nucleolar localization (Figure 4).
Int. J. Mol. Sci. 2016, 17, 1721 5 of 10 
 
2.4. Application of Anti-S-HDAg Antibodies for Immunofluorescence 
Finally, we sought to evaluate to applicability of the sera for the detection of HDV antigens by 
fluorescent/confocal microscopy. Huh7.5 cells were seeded on glass coverslips and transfected with 
pDL444 encoding S-HDAg, or pDL445 encoding L-HDAg and let them grow for 24 to 48 h. Two 
protocols were used to fix the cells. Methanol-acetone protocol was applied to fix cells 24 h 
posttransfection, whereas cells at 48 h posttransfection were fixed by formaldehyde. In both cases, 
anti-S-HDAg antibodi s efficiently stained both small and large HDV antigens (Figure 4). In lines 
with the earlier observations [21], both antigens exhibited nucleolar oc l zation (Figure 4). 
 
Figure 4. Detection of small (S) and large (L) HDV antigens in Huh7.5 cells by the immunofluorescent 
staining with polyclonal rabbit antibodies specific to S-HDAg. In brief, Huh7.5 cells were transfected 
with pDL444 encoding S-HDAg, or pDL445 encoding large HDV antigen (L-HDAg), or control 
pCMV1 (as depicted on the left side). Cells were grown for 24 h and fixed with methanol-acetone (a); 
or grown for 48 h and fixed with paraformaldehyde (b). Vertical panels left to right: staining with 
anti-S-HDAg rabbit serum (#100-3a) and FITC-conjugated anti-rabbit antibodies (anti-S-HDAg; 
green); DAPI for nucleus (DAPI, blue); overlay of anti-S-HDAg and nuclear staining (merge). The 
large white bar on panel (a) for pCMV1 and pDL444 plasmids denote 25 μm, whereas the small bar on 
panel (a) for plasmid pDL445 and on panel (b) denotes 10 μm. 
Figure 4. Detection of small (S) and large ( ) antigens in Huh7.5 cells by the immun fluorescent
staining with polyclonal rabbit antibodies specific to S- Ag. In brief, Huh7.5 cells were transfected
with pDL444 encoding S-HDAg, or pDL445 encoding large HDV antigen (L-HDAg), or control pCMV1
(as depicted on the left side). Cells were grown for 24 h and fixed with methanol-acetone (a); or grown
for 48 h and fixed with paraformaldehyde (b). Vertical panels left to right: staining with anti-S-HDAg
rabbit serum (#100-3a) and FITC-conjugated anti-rabbit antibodies (anti-S-HDAg; green); DAPI for
nucleus (DAPI, blue); overlay of anti-S-HDAg and nuclear staining (merge). The large white bar on
panel (a) for pCMV1 and pDL444 plasmids denote 25 µm, whereas the small bar on panel (a) for
plasmid pDL445 and on panel (b) denotes 10 µm.
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3. Materials and Methods
3.1. Reagents
Protease inhibitor cocktail used in the protein purification was from Sigma (St. Louis, MO,
USA). The empty pCMV1 vector was purchased from Invitrogen (Carlsbad, CA, USA). The primary
antibodies to β-actin were from Abcam (ab3280). HRP-conjugated secondary antibodies against rabbit
(sc-2004) or mouse (sc-2005) immunoglobulins were purchased from Santa-Cruz Biotechnology (Dallas,
TX, USA). FITC-conjugated anti-rabbit antibodies were from Jackson ImmunoResearch Labolatories
(West Grove, PA, USA). Plasmids pDL444 and pDL445 directing the expression of S-HDAg and
L-HDAg in the mammalian cells were a kind gift of David Lazinski (Tufts University, Boston, MA,
USA) and Severin Gudima (University of Kansas Medical Center, KS, USA). Human hepatoma Huh7.5
cell line was kindly provided by C.M. Rice (The Rockefeller University, NY, USA) and Apath L.L.C.
(NY, USA).
3.2. Plasmid Construction
The plasmid for prokaryotic expression of S-HDAg was constructed based on the pET-21d
vector (Novagen, Madison, WI, USA). The fragment encoding S-HDAg was amplified from
the plasmid pDL444 [22] using primers 5′-AAAAAAAACCATGGCTCGGTCCGAGTCG-3′ and
5′-ATAAAGCTTTCAGTGGTGGTGGTGGTGGTGTGGAAATCCCTGGTTTCCC-3′, digested with
NcoI and HindIII endonucleases and cloned into the respective sites of pET-21d vector. The structure of
the resulting plasmid pET-21d-SHDAg was verified by sequencing using ABI PRISM® BigDye™
Terminator v. 3.1 reagents with the subsequent analysis of products on an automatic Applied
Biosystems 3730 DNA Analyzer (CCU “Genome”, EIMB, Moscow, Russia).
3.3. Protein Expression and Purification
The plasmid pET-21d-SHDAg was transformed into Rosetta (DE3) E. coli strain. A single colony
was inoculated into 10 mL of LB medium supplemented with 150 mg/L ampicillin and 15 mg/L
chloramphenicol and grown overnight at 37 ◦C. Five mL of the culture was added to 500 mL of fresh
medium supplemented with the same antibiotics, and the cells were grown at 37 ◦C until the optical
density reached 0.5–0.6 (measured at 550 nm). Protein synthesis was then induced by the addition of
isopropyl-β-D-1-thiogalactopyranoside (IPTG) to the final concentration of 1 mM. Cells were grown for
additional 4 h, collected by centrifugation (15 min, 3200× g), washed with 20 mL of buffer A (25 mM
Tris-HCL, pH 7.6, 50 mM glucose, 10 mM EDTA), and stored at −70 ◦C.
The cell pellet was suspended in 25 mL of buffer B (25 mM Tris-HCl, pH 7.5, 300 mM NaCl,
1 mM 2-mercaptoethanol, 10% (v/v) glycerol, 1 mM PMSF, 0.1% (v/v) protease inhibitor cocktail)
supplemented with 0.5% (v/v) triton X-100. The suspension was lysed by sonication on ice (Bandelin
Sono Plus apparatus, 7 × 45 s impulses with 2 min gaps). Cell debris was removed by centrifugation
at the 16,000× g for 10 min, and the clarified lysate was loaded onto a 2-mL Ni-NTA His-NTA agarose
(Qiagen, Dusseldorf, Germany) column. The eluate collected after loading was re-applied onto the
column one to two times to increase target protein binding. The resin was washed with buffer B,
then buffer B supplemented with 10, then 30, then 40 mM imidazole (20 mL each). The target protein
was eluted with buffer B supplemented with 200 mM imidazole, and 0.5 mL fractions were collected.
Level of the protein in each fraction was estimated using Coomassie R-250 dye staining. Fractions
containing the highest amount of S-HDAg were pooled, dialyzed overnight against 200 mL of 25 mM
Tris-HCl buffer (pH 7.5) supplemented with 300 mM NaCl, 1 mM 2-mercaptoethanol, 1 mM PMSF,
and 10% (v/v) glycerol and put at +4 ◦C, to be used for immunization within 24 h after protein
purification. For longer storage, recombinant S-HDAg dialyzed against the same buffer containing
50% (v/v) glycerol and frozen at −20 to −80 ◦C.
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3.4. Rabbit Immunization
All animal experiments were performed in accordance with the Russian Federation law and
approval for the rabbit immunizations issued by the local ethical committee for the animal experiments.
Rabbits of the Moscow strain of grey Chinchilla (female, 2 month old, 1.5 to 1.8 kg) were obtained
from the laboratory animal breeder “KrolInfo” (Orekhovo-Zuevo, Moscow region, Russia, available
online: http://krolinfo.umi.ru). Animals were maintained at 20 to 22 ◦C and a relative humidity of
50% ± 10% on a 12-h light/dark cycle, fed with commercial rodent chow and herbal vitamin flour
(Zoomir, Moscow, Russia) and provided with the tap water ad libitum. The treatment of animals
was in accordance with the regulations outlined in the USDA Animal Welfare Act and the conditions
specified in the Guide for care and use of laboratory animals [23].
Rabbits no. 99 and no. 100 were immunized with the injections of the recombinant S-HDAg.
On day 1 animals were primed with 80 µg of S-HDAg in 400 µL PBS mixed (1:1 v/v) with the complete
Freund Adjuvant (CFA), and on day 7, with the same dose administered with the incomplete Freund
Adjuvant (IFA). Primes were given with 20 gauge needles as four widely separated subcutaneous
injections along the back (4 times 20 µg in the total of 200 µL). Animals were boosted four times with
one month intervals by intravenous injections of 40 µg of S-HDAg in 200 µL PBS mixed with IFA
(1:1 v/v) split into two injections into the ear veins. Due to the protein instability, each booster injection
was done with a freshly prepared protein preparation. Two control animals received same injections
without S-HDAg. Rabbits were bled from the ear vein two weeks post each immunization. Additional
bleedings were done within one month after the main bleedings 2–4 and dubbed 2b, 3b, 3c, 4b, and 4c,
respectively. Sera were aliquoted and stored at −20 ◦C until further use.
3.5. ELISA
Rabbit sera were assessed for the levels of antibodies against S-HDAg. For this, freshly purified
S-HDAg was diluted in PBS at 0.3 µg/mL and coated onto 96-well MaxiSorp plates (Nunc, Roskilde,
Denmark) by overnight incubation at 6–8 ◦C. Coated plates were blocked with PBS containing 1% BSA
for 1 h at room temperature. Rabbit sera were serially diluted in the range 103 to 109 in PBS containing
0.05% Tween 20, 0.5% BSA, 2% goat serum (all from Sigma) (Scan buffer). The prediluted rabbit
sera were applied on the plates in the amount of 100 µL per well and incubated overnight at 6–8 ◦C.
After incubation, sera were discarded, plates were washed six times with PBS containing 0.05%
Tween 20, and filled 100 µL per well with the horseradish peroxidase-conjugated goat anti-rabbit
secondary antibody (DAKO, Glostrup, Denmark) diluted in Scan buffer. After 1.5 h incubation at
37 ◦C, secondary antibodies were discarded, plates were washed six times as above and treated 100 µL
per well with the liquid substrate 3,3′,5,5′-tetramethylbenzidine (TMB) pre-diluted 1:10 in the substrate
buffer (both from Medico-Diagnostic Laboratory, Moscow, Russia). Color was developed for 15 min at
room temperature in the dark, reaction was stopped by adding 50 µL per well of 2.5 M sulfuric acid.
Plates were read on the automatic reader (Multiscan EX, Thermo Electron Corporation, Waltham, MA,
USA) at a dual length of 450 versus 620 nm. The average optical absorption values demonstrated by
the naïve and control rabbit sera at each of the dilutions, and standard deviation (STDEV) of each
individual serum from the average were calculated. Cut-off values to discriminate sera containing the
specific antibodies from the negative sera were defined as an average OD450–620 of the preimmune
and control rabbit sera at the given dilution plus 3 STDEV. OD450–620 values of all serum samples and
the cut-off values were plotted on a logarithmic scale to generate the titration curves. The end-point
titer of specific antibodies was determined as the dilution factor at which the optical absorption of a
sample crossed the cut-off curve.
3.6. Cell Culture and Transfection
Huh7.5 cells were maintained as previously described [24,25]. The cells were seeded onto 6-well
plates at a density of 3 × 105 cells/well, 24 h prior to transfection. Transfections were carried out using
Int. J. Mol. Sci. 2016, 17, 1721 8 of 10
Turbofect reagent (Thermo Scientific, Rockford, IL, USA). The complexes were obtained by mixing
2 µg/well of plasmids with 4 µL/well Turbofect in 400 µL/well OPTI-MEM medium with subsequent
incubation at room temperature for 25 min. The complexes were added to the cells, 3 h later the
medium was replaced with the fresh one, and 30 or 48 h posttransfection the cells were harvested by
scrapping and stored at −70 ◦C.
3.7. Western Blot Analysis
The recombinant S-HDAg was dissolved or a pellet of Huh7.5 cells was resuspended in the
Laemmli buffer, incubated at 100 ◦C for 5 min and applied onto 15% SDS-polyacrylamide gel.
After electrophoresis, the proteins were transferred to a Hybond ECL membrane (GE Healthcare).
The membrane was blocked with 5% (w/v) non-fat milk in PBS supplemented with 0.05% (v/v)
Tween 20 (PBST), incubated with anti-S-HDAg rabbit serum diluted 1000 to 1:60,000 in PBST at 4 ◦C
overnight, washed with PBST (3 × 7 min), incubated with HRP-conjugated anti-rabbit antibodies
(1:3000 dilution) for 1 h at room temperature and washed with PBST (3 × 7 min). The bands were
visualized using Pierce ECL Western Blotting Substrate or Super Signal West Femto Maximum
Sensitivity Substrate reagents from Termo Scientific using ChemiDoc MP equipment (Bio-Rad,
Hercules, CA, USA).
3.8. Immunofluorescence
Huh7.5 were seeded at 15,000 cell/well density on the glass coverslips placed into a 6-well plate.
On the next day, the cells were transfected with pDL444, or PDL445, or control pCMV1 plasmids using a
Lipofectamin LTX reagent (Termo Scientific) according to the manufacturer’s instructions. Twenty four
hours later, the cells were washed with PBS, fixed with a methanol:acetone (1:1) mixture, kept at−20 ◦C
overnight, and then rehydrated in PBS by incubation during 30 min at room temperature. Alternatively,
48 h posttransfection the cells were washed, fixed by incubation with 2% formaldehyde for 15 min at
room temperature, treated with 0.5% Triton X-100 for 5 min, and washed with PBS. Following fixation,
the cells were stained for 1 h at room temperature with hyperimmune rabbit serum #100-3a (Figure 2)
diluted in the Blocking buffer (PBS, 2% (w/v) bovine serum albumin, 0.2% (v/v) Tween 20, 10% (v/v)
glycerol). After that, cells were washed with PBS three times and incubated for 45 min with goat
anti-rabbit antibodies conjugated with FITC diluted in the Blocking buffer. After washing with PBS,
the cells were incubated with 300 nM solution of DAPI in PBS for 5 min and rinsed with PBS. Finally,
coverslips were mounted on the microscopic slides with cells facing the slide, using VECTASHIELD®
Antifade Mounting Medium (Vector labs, Burlingame, CA, USA). The fluorescence was analyzed on
the confocal laser scanning microscope Leica TCS5 with a 63× objective.
4. Conclusions
To conclude, we have expressed and purified small antigen of hepatitis delta virus S-HDAg that
was further used to obtain specific anti-S-HDAg antibodies in an extremely high titer. Antibodies
were successfully applied for the sensitive detection of both small and large HDV antigens in ELISA,
Western blotting and immunofluorescence assays. These antibodies can be further used for medical
studies as well as for the HDV-focused research.
Supplementary Materials: Supplementary materials can be found at www.mdpi.com/1422-0067/17/10/1721/s1.
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